CAB EGFR x CD3

**CAB EGFR x CD3** is an experimental **conditionally active bispecific monoclonal antibody** designed to engage **epidermal growth factor receptor** on tumor cells and **CD3** on T cells, thereby redirecting T-cell cytotoxicity against EGFR-expressing solid tumors. The name indicates a member of BioAtla-style **Conditionally Active Biologic** programs in which binding is engineered to be favored in the acidic tumor microenvironment and reduced in normal tissues, with the goal of widening the therapeutic window for EGFR-directed T-cell engagers. However, based on the available public information, this exact name appears to refer to a **preclinical program descriptor rather than a clearly disclosed, uniquely identified clinical drug asset with a confirmed code name**, so the entry should be treated as a specific but incompletely characterized investigational EGFR x CD3 CAB bispecific program.

Other names

anti-EGFR x CD3 conditionally active biologic bispecific antibodyCAB EGFR x CD3 bispecific T-cell engager